Yao, M.; Sturdivant, J.; Ebrahimi, A.; Ganguly, S.; Elbayoumi, T.
Novel Pharmaceutical Strategy for Selective Abrogation of TSP1-Induced Vascular Dysfunction by Decoy Recombinant CD47 Soluble Receptor in Prophylaxis and Treatment Models. Biomedicines 2021, 9, 642.
https://doi.org/10.3390/biomedicines9060642
AMA Style
Yao M, Sturdivant J, Ebrahimi A, Ganguly S, Elbayoumi T.
Novel Pharmaceutical Strategy for Selective Abrogation of TSP1-Induced Vascular Dysfunction by Decoy Recombinant CD47 Soluble Receptor in Prophylaxis and Treatment Models. Biomedicines. 2021; 9(6):642.
https://doi.org/10.3390/biomedicines9060642
Chicago/Turabian Style
Yao, Molly, Jalicia Sturdivant, Aren Ebrahimi, Samayita Ganguly, and Tamer Elbayoumi.
2021. "Novel Pharmaceutical Strategy for Selective Abrogation of TSP1-Induced Vascular Dysfunction by Decoy Recombinant CD47 Soluble Receptor in Prophylaxis and Treatment Models" Biomedicines 9, no. 6: 642.
https://doi.org/10.3390/biomedicines9060642
APA Style
Yao, M., Sturdivant, J., Ebrahimi, A., Ganguly, S., & Elbayoumi, T.
(2021). Novel Pharmaceutical Strategy for Selective Abrogation of TSP1-Induced Vascular Dysfunction by Decoy Recombinant CD47 Soluble Receptor in Prophylaxis and Treatment Models. Biomedicines, 9(6), 642.
https://doi.org/10.3390/biomedicines9060642
